ImmuCell Corporation last reported quarterly results on Oct 13, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026). It usually reports 8–13 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–13 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 13, 2026
13 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
—
|
—
|
|
Jul 9, 2026
9 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
7
+11.5%
|
2
+265.6%
|
0.20
+233.3%
|
|
Apr 8, 2026
8 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
10
+28.4%
|
2
+34.2%
|
0.21
+31.2%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
8
-1.6%
|
-3
-653.7%
|
-0.31
-646.9%
|
|
Oct 7, 2025
7 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
6
-8.4%
|
-0
+80.1%
|
-0.02
+77.8%
|
|
Jul 9, 2025
9 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
6
+17.8%
|
1
+132.8%
|
0.06
+130.0%
|
|
Apr 8, 2025
8 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
8
+11.2%
|
1
+430.5%
|
0.16
+366.7%
|
|
Jan 10, 2025
10 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
8
+52.1%
|
1
+145.1%
|
0.06
+139.2%
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ICCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Portland, ME
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 811641
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.